Raglan has a long and successful history of providing corporate finance and investment banking services to a range of Irish and international companies. For the last number of years, Raglan ceased to provide any third-party corporate finance services and is now solely focused upon creating our own companies in-house that can then be rapidly listed on the London stock exchange. Our aim is to complete an IPO within two years post inception of the company. This approach creates value for our shareholders and helps our portfolio companies prepare for the next the next stage of their growth.

In 2017, Raglan established a niche pharma services company, Open Orphan, following on from the success of its first rare disease pharma company, Amryt Pharma plc. Open Orphan is a fast-growing niche CRO pharmaceutical services company, which is the world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.

Open Orphan plc is comprised of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and is also building out a valuable data platform business. It has offices in London, Dublin, Paris, and the Netherlands. Open Orphan completed its IPO in June 2019 through its reverse takeover of Venn Life Sciences and, in January 2020, it completed a merger with hVIVO. It is now listed on the London AIM stock exchange and the Euronext growth exchange. Open Orphan is led by an experienced Board and leadership team with deep industry and financial expertise.

Previously, Raglan established Amryt Pharma Plc which is also listed on the London AIM, Dublin Euronext and the NASDAQ exchanges. Following Amryt’s acquisition of Aegerion Pharmaceuticals in September 2019, it held a market capitalisation in excess of £281m in June 2020 and is now an established European and North America orphan drug company. The company is experiencing significant growth in monthly sales revenues while at the same time, it is managing a pipeline of drugs in development including a potential blockbuster EB orphan drug, which is now in its final FDA Phase III trials.

Raglan has also been very active in the Oil & Gas sector for many years, therefore having an in-depth knowledge of the industry having advised on, and participated in, a variety of related projects. Raglan established Fastnet Oil & Gas plc which floated on the London and Dublin stock exchanges raising over $50m.

The team behind Raglan Capital have many years of deal making experience with a proven track record of achieving exceptional results.

Raglan has offices in Dublin, London and Vienna. Our relationships include regular contact with Dublin-based and international stockbrokers, investment banks, private equity firms and a broad range of investors. This provides Raglan Capital with invaluable access to local advisers and contacts when completing international transactions.